Industry
Valeant Pharma investing in R&D; All eyes on Q4 results
Drug maker Valeant Pharmaceuticals International Inc is facing a variety of problems. Valeant has changed its aggressive investment strategy and turned keen on research and development. Valeant is also facing Federal investigation over its pricing strategies.
Japanese regional banks up lending on auto, holiday spending
Japan's regional banks are enhancing unsecured retail lending as it offers high profit margins. Loans on mortgage and small firm borrowing are declining. Japan banks are suffering from ultra-low interest rate regime to increase revenues.
US Presidential elections, China economy setting tone for markets
Global markets have been moving in tandem with state of Chinese economy and US Presidential elections these days. After rebounding in the previous month, the global markets are waiting for next level triggers from US elections and stimulus plans on China's economy.
Intel mulls over selling $1-bln assets of venture capital unit
Intel Corp, one of the major manufacturer of computer components in the world, is planning to sell a part of its venture capital (VC) unit Intel Capital. The value of the part of assets to be offered for sale is estimated to be $1billion worth. UBS Group AG has been appointed to find out potential buyers for the sale of a part in venture capital unit.